- Preparation process of N-(2-acetamido)-2-aminoethanesulfonic acid
-
The invention discloses a preparation process of N-(2-acetamido)-2-aminoethanesulfonic acid. The preparation process comprises the following steps: subjecting a compound 1 with a structure as shown inthe specification to reacting with a compound 2 with a structure as shown in the specification so as to obtain a first intermediate product with a structure as shown in the specification; subjectingthe first intermediate product to reacting with at least one of a sulfur-containing reagent and an oxidation reagent to obtain a second intermediate product with a structure shown in the specificationor a salt thereof; and subjecting the second intermediate product or the salt thereof to reacting with a nitrogen-containing reagent to obtain N-(2-acetamido)-2-aminoethanesulfonic acid. In the formulas of the invention, A and X are respectively one selected from the group consisting of halogen, OH, SH and NH2, and at least one of A and X is NH2; Y is one selected from the group consisting of halogen, OH and SH; and Z is one selected from the group consisting of OH, OR, OM, SH and SR. The process has the advantages that the price of initial raw materials and production cost are low; reactionconditions are mild; purification process is simple; the yield of N-(2-acetamido)-2-aminoethanesulfonic acid is high; and the whole preparation process is simple, easy to control and beneficial for large-scale production.
- -
-
Paragraph 0074-0075; 0082-0090
(2020/11/23)
-
- Stabilizing labeled antibody using amino acids
-
The present invention relates to a method for stabilizing a labeled antibody in a solution, in which the labeled antibody is stabilized by allowing the labeled antibody to be present together with at least one of amino acid and a derivative thereof in the solution.
- -
-
-
- Isolation of nucleic acids
-
A method for extracting nucleic acids from a biological material such as blood comprises contacting the mixture with a material at a pH such that the material is positively charged and will bind negatively charged nucleic acids and then eluting the nucleic acids at a pH when the said materials possess a neutral or negative charge to release the nucleic acids. The nucleic acids can be removed under mildly alkaline conditions to the maintain integrity of the nucleic acids and to allow retrieval of the nucleic acids in reagents that are immediately compatible with either storage or analytical testing.
- -
-
-
- Isolation of nucleic acids
-
A method for extracting nucleic acids from a biological material such as blood comprises contacting the mixture with a material at a pH such that the material is positively charged and will bind negatively charged nucleic acids and then eluting the nucleic acids at a pH when the said materials possess a neutral or negative charge to release the nucleic acids. The nucleic acids can be removed under mildly alkaline conditions to the maintain integrity of the nucleic acids and to allow retrieval of the nucleic acids in reagents that are immediately compatible with either storage or analytical testing.
- -
-
-
- Zwitterionic compounds and their n-halo derivatives for use in the treatment of clinical conditions
-
Zwitterionic compounds selected from: taurine (2-aminoethanesulphonic acid), 2(N-morpholino)ethanesulphonic acid (MES), N-(2-acetamido)iminodiacetic acid (ADA), piperazine-N,N'bis(2-ethanesulphonic acid (PIPES), N-(2-acetamido)-2-aminoethanesulphonic acid (ACES), N,N-bis(2-hydroxyethyl)-2-aminoethanesulphonic acid (BES), 3-(N-morpholino)propanesulphonic (MOPS), N-N[tris(hydroxymethyl)-methyl]-2-aminoethanesulphonic acid (TES), N-2-hydroxyethylpiperazine-N'-2-ethanesulphonic acid (HEPES), N-2-hydroxyethylpiperazine-N'3-propanesulphonic acid (H)EPPS), 2-(cyclohexylamino)ethanesulphonic acid (CHES) or 3-(cyclohexylamino)propanesulphonic acid (CAPS), and their N-halo derivatives can be used separately or in combination in the treatment of related clinical conditions by stimulating myeloperoxidase activity, which in turn stimulates hypochlorous acid production in vivo, which leads inter alia to enhanced leukotriene inactivation.
- -
-
-
- Use of zwitterionic compounds and their N-halo derivatives
-
Zwitterionic compounds selected from:, taurine (2-aminoethanesulphonic acid), 2(N-morpholino)ethanesulphonic acid (MES), N-(2-acetamido) iminodiacetic acid (ADA), piperazine-N,N?bis(2-ethanesulphonic acid (PIPES), N-(2-acetamido)-2-aminoethanesulphonic acid (ACES), N,N-bis(2-hydroxyethyl)-2-aminoethanesulphonic acid (BES), 3-(N-morpholino)propanesulphonic (MOPS), N-N[tris(hydroxymethyl)-methyl]-2-aminoethanesulphonic acid (TES), N-2-hydroxyethylpiperazine-N?-2-ethanesulphonic acid (HEPES), N-2-hydroxyethylpiperazine-N?3-propanesulphonic acid ((H)EPPS), 2-(cyclohexylamino) ethanesulphonic acid (CHES) or 3-(cyclohexylamino) propanesulphonic acid (CAPS), and their N-halo derivatives can be used separately or in combination in the treatment of related clinical conditions by stimulating myeloperoxidase activity, which in turn stimulates hypochlorous acid production in vivo, which leads inter aliato enhanced leukotriene inactivation.
- -
-
-
